InfanDx AG is a privately held company focusing on the development and commercialization of novel diagnostic solutions for child health. Lead by a team of seasoned industry experts, InfanDx initially focused on the development of a test for the early detection of hypoxic-ischemic encephalopathy.
The Company shifted focus in 2023 to non-invasive prenatal screening. Based on a proprietary in-licensed technology InfanDx aims to take non-invasive prenatal testing beyond the current scope of chromosome copy number variations (aneupolodies) and large structural variations of DNA to testing of microdeletions and point mutations causative to a large number of genetic diseases. The initial focus of InfanDx's product pipeline lies on taking functional newborn screening for common monogenetic conditions, the current standard-of-care, to an early prenatal stage by non-invasive prenatal genetic screening.
The Company is headquartered in Cologne, Germany, with a branch office in Berlin, Germany, and a wholly owned subsidiary in Boston, MA, USA.
